(VIANEWS) – Moderna (MRNA), Pfizer (PFE), Clean Harbors (CLH) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Moderna (MRNA)

1202.8% sales growth and 72.43% return on equity

Moderna’s sales growth this year is anticipated to be 2434.2% and a negative 2.5% for next year.

Year-on-year quarterly revenue growth grew by 6398.5%, now sitting on 7.02B for the twelve trailing months.

Volume

Today’s last reported volume for Moderna is 4784980 which is 47.19% below its average volume of 9061310.

Moderna’s sales growth for the next quarter is 1202.8%. The company’s growth estimates for the ongoing quarter and the next is 1694.9% and 1681.2%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 72.43%.

Volatility

Moderna’s last day, last week, and last month’s current intraday variation average was 3.71%, 2.98%, and 3.26%, respectively.

Moderna’s highest amplitude of average volatility was 5.89% (day), 6.80% (last week), and 6.91% (last month), respectively.

Moderna’s Stock Yearly Top and Bottom Value

Moderna’s stock is valued at $136.46 at 19:22 EST, way below its 52-week high of $497.49 and way higher than its 52-week low of $102.66.

Moderna’s Moving Average

Moderna’s worth is way below its 50-day moving average of $298.96 and way below its 200-day moving average of $267.83.

Previous days news about Moderna(MRNA)

  • Arbutus hits Moderna with new suit claiming Covid-19 vaccine patent(s). According to Benzinga on Monday, 28 February, "They said Moderna had licensed Arbutus technology before - but not for the application in COVID-19.", "Before the pandemic, Moderna obtained licenses to use Arbutus’s LNP patents for certain mRNA products directed to specific viral targets. "
  • According to The New York Times on Monday, 28 February, "Pfizer-BioNTech, Moderna and Johnson and Johnson are all testing Omicron-specific versions of their vaccines."
  • According to Bloomberg Quint on Friday, 4 March, "The world’s third-largest economy currently relies on shots from Pfizer Inc. and Moderna Inc. for the bulk of its supplies."

2. Pfizer (PFE)

108.8% sales growth and 14.03% return on equity

Pfizer Inc. develops, manufactures, and sells healthcare products worldwide.

Pfizer’s sales growth this year is expected to be 91.3% and a negative 12.9% for next year.

Year-on-year quarterly revenue growth grew by 44.6%, now sitting on 46.41B for the twelve trailing months.

Volume

Today’s last reported volume for Pfizer is 29759500 which is 25.29% below its average volume of 39837600.

Pfizer’s sales growth for the next quarter is 108.8%. The company’s growth estimates for the present quarter and the next is 50% and 150%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.03%.

Volatility

Pfizer’s last day, last week, and last month’s current intraday variation average was 0.27%, 2.33%, and 1.96%, respectively.

Pfizer’s highest amplitude of average volatility was 2.32% (day), 3.36% (last week), and 2.97% (last month), respectively.

Pfizer’s Stock Yearly Top and Bottom Value

Pfizer’s stock is valued at $48.65 at 19:22 EST, below its 52-week high of $51.86 and way above its 52-week low of $33.36.

Pfizer’s Moving Average

Pfizer’s worth is way higher than its 50-day moving average of $43.57 and way above its 200-day moving average of $42.49.

Previous days news about Pfizer(PFE)

  • According to Bloomberg Quint on Monday, 28 February, "Viatris was formed in November 2020, through the combination of Mylan and Upjohn (a unit of Pfizer earlier). "
  • According to MarketWatch on Monday, 28 February, "Viatris Inc. , the company formed by the merger of Mylan and Pfizer Inc. unit Upjohn in 2020, said Monday it has reached an agreement to combine its biosimilars portfolio with Biocon Biologics Ltd. "
  • According to Bloomberg Quint on Monday, 28 February, "While other therapies for the liver condition from Alnylam Pharmaceuticals Inc. and Pfizer Inc. require repeated dosing, a Crispr fix has the potential to be permanent."
  • According to Bloomberg Quint on Monday, 28 February, "The vaccine made by Pfizer Inc. and partner BioNTech SE is much less effective in preventing infection in children ages 5 to 11 years than in older adolescents or adults, according to a large new set of data collected by health officials in New York state, the New York times reported.", "The Pfizer vaccine still prevents severe illness in the children but offers virtually no protection against infection, even within a month after full immunization, the data, which were collected during the omicron surge, suggest, according to the newspaper."

3. Clean Harbors (CLH)

29.9% sales growth and 13.99% return on equity

Clean Harbors, Inc. provides environmental and industrial services in North America.

Clean Harbors’s sales growth this year is anticipated to be 18.1% and 19.9% for next year.

Year-on-year quarterly revenue growth grew by 22.1%, now sitting on 3.48B for the twelve trailing months.

Volume

Today’s last reported volume for Clean Harbors is 245333 which is 31.05% below its average volume of 355851.

Clean Harbors’s sales growth for the next quarter is 29.9%. The company’s growth estimates for the current quarter and the next is 7.9% and 73.8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.99%.

Volatility

Clean Harbors’s last day, last week, and last month’s current intraday variation average was 0.04%, 0.97%, and 1.49%, respectively.

Clean Harbors’s highest amplitude of average volatility was 2.26% (day), 2.20% (last week), and 3.04% (last month), respectively.

Clean Harbors’s Stock Yearly Top and Bottom Value

Clean Harbors’s stock is valued at $95.53 at 19:22 EST, way below its 52-week high of $118.89 and way above its 52-week low of $81.30.

Clean Harbors’s Moving Average

Clean Harbors’s value is under its 50-day moving average of $95.64 and under its 200-day moving average of $98.89.

4. VALE (VALE)

17.4% sales growth and 29.06% return on equity

Vale S.A., together with its subsidiaries, produces and sells iron ore and iron ore pellets for use as raw materials in steelmaking in Brazil and internationally.

VALE’s sales growth this year is anticipated to be 55.9% and a negative 12.8% for next year.

Year-on-year quarterly revenue growth grew by 121.8%, now sitting on 246.58B for the twelve trailing months.

Volume

Today’s last reported volume for VALE is 28262800 which is 13.22% below its average volume of 32568600.

VALE’s sales growth for the next quarter is 17.4%. The company’s growth estimates for the current quarter and the next is 169.5% and 664.7%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.06%.

Volatility

VALE’s last day, last week, and last month’s current intraday variation average was 1.90%, 2.45%, and 2.51%, respectively.

VALE’s highest amplitude of average volatility was 2.34% (day), 3.54% (last week), and 3.64% (last month), respectively.

VALE’s Stock Yearly Top and Bottom Value

VALE’s stock is valued at $20.15 at 19:22 EST, way under its 52-week high of $23.18 and way above its 52-week low of $11.41.

VALE’s Moving Average

VALE’s value is way higher than its 50-day moving average of $13.71 and higher than its 200-day moving average of $19.03.

5. Investors Bancorp (ISBC)

11% sales growth and 10.65% return on equity

Investors Bancorp, Inc. operates as the bank holding company for Investors Bank that provides various banking products and services to individuals and businesses in the United States.

Investors Bancorp’s sales growth this year is anticipated to be 6.3% and 6.1% for next year.

Year-on-year quarterly revenue growth grew by 15.7%, now sitting on 882.02M for the twelve trailing months.

Volume

Today’s last reported volume for Investors Bancorp is 2241450 which is 7.21% below its average volume of 2415650.

Investors Bancorp’s sales growth for the next quarter is 11%. The company’s growth estimates for the present quarter and the next is 14.3% and 3.2%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.65%.

Volatility

Investors Bancorp’s last day, last week, and last month’s current intraday variation average was 1.02%, 2.40%, and 1.52%, respectively.

Investors Bancorp’s highest amplitude of average volatility was 3.00% (day), 3.66% (last week), and 2.67% (last month), respectively.

Investors Bancorp’s Stock Yearly Top and Bottom Value

Investors Bancorp’s stock is valued at $16.74 at 19:22 EST, under its 52-week high of $17.67 and way above its 52-week low of $12.60.

Investors Bancorp’s Moving Average

Investors Bancorp’s worth is above its 50-day moving average of $16.31 and way above its 200-day moving average of $15.08.

6. BorgWarner (BWA)

7.6% sales growth and 9.14% return on equity

BorgWarner Inc. provides solutions for combustion, hybrid, and electric vehicles worldwide.

BorgWarner’s sales growth this year is anticipated to be 11.1% and 11.1% for next year.

Year-on-year quarterly revenue growth declined by 6.9%, now sitting on 14.84B for the twelve trailing months.

Volume

Today’s last reported volume for BorgWarner is 1713550 which is 4.43% below its average volume of 1793080.

BorgWarner’s sales growth for the next quarter is 7.6%. The company’s growth estimates for the ongoing quarter and the next is a negative 24% and negative -0.9%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.14%.

Volatility

BorgWarner’s last day, last week, and last month’s current intraday variation average was 2.43%, 2.25%, and 1.57%, respectively.

BorgWarner’s highest amplitude of average volatility was 3.30% (day), 3.83% (last week), and 3.60% (last month), respectively.

BorgWarner’s Stock Yearly Top and Bottom Value

BorgWarner’s stock is valued at $43.56 at 19:22 EST, way below its 52-week high of $55.55 and above its 52-week low of $40.28.

BorgWarner’s Moving Average

BorgWarner’s value is below its 50-day moving average of $45.15 and below its 200-day moving average of $46.48.

7. Provident Bancorp (PVBC)

5.1% sales growth and 6.87% return on equity

Provident Bancorp, Inc. operates as the bank holding company for The Provident Bank that provides various financial services to individuals and small businesses in the United States.

Provident Bancorp’s sales growth this year is expected to be 6.1% and 9.3% for next year.

Year-on-year quarterly revenue growth grew by 6.4%, now sitting on 62.71M for the twelve trailing months.

Volume

Today’s last reported volume for Provident Bancorp is 20099 which is 42.33% below its average volume of 34853.

Provident Bancorp’s sales growth for the next quarter is 5.1%. The company’s growth estimates for the ongoing quarter and the next is 4.2% and 38.9%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.87%.

Provident Bancorp’s Stock Yearly Top and Bottom Value

Provident Bancorp’s stock is valued at $17.00 at 19:22 EST, way below its 52-week high of $20.14 and way above its 52-week low of $12.20.

Provident Bancorp’s Moving Average

Provident Bancorp’s value is below its 50-day moving average of $17.91 and under its 200-day moving average of $17.09.